Stock RVV REVIVE THERAPEUTICS LTD
Add to a list
To use this feature you must be a member
Log inSign up

Company Revive Therapeutics Ltd Toronto S.E.

Equities

RVV

CA7615161030

Biotechnology & Medical Research

Delayed Toronto S.E.
Other stock markets
 		5-day change 1st Jan Change
- CAD -.--% Intraday chart for Revive Therapeutics Ltd +6.67% -11.11%
Apr. 23 FDA Grants Revive Therapeutics Type C Meeting Request For Bucillamine Study to Treat Long COVID MT
Apr. 23 Revive Therapeutics Brief: Announcing Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID MT

Business Summary

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.

Managers

Managers TitleAgeSince
Michael Frank CEO
 Chief Executive Officer - 19-12-17
Carmelo Marrelli DFI
 Director of Finance/CFO 53 -

Members of the board

Members of the board TitleAgeSince
Michael Frank CEO
 Chief Executive Officer - 19-12-17
William Jackson BRD
 Director/Board Member - 13-12-31
Andrew Lindzon BRD
 Director/Board Member 63 19-12-17
Christian Scovenna BRD
 Director/Board Member 50 19-12-17
Joshua Herman BRD
 Director/Board Member - 19-12-17

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 418,564,269 412,444,735 ( 98.54 %) 0 98.54 %

Shareholders

NameEquities%Valuation
Michael Frank
0.7377 %
2,638,500 0.7377 % 55 409 $
Christian Scovenna
0.5592 %
2,000,000 0.5592 % 42 000 $
William Jackson
0.1817 %
650,000 0.1817 % 13 650 $
Joshua Herman
0.1748 %
625,334 0.1748 % 13 132 $
Andrew Lindzon
0.0575 %
205,700 0.0575 % 4 320 $
Gofen & Glossberg LLC
0.0363 %
130,000 0.0363 % 2 730 $
Hilton Capital Management LLC
0.0350 %
125,000 0.0350 % 2 625 $
MAI Capital Management LLC
0.006990 %
25,000 0.006990 % 525 $
FineMark National Bank & Trust
0.002893 %
10,345 0.002893 % 217 $
Able Wealth Management LLC
0.000140 %
500 0.000140 % 11 $

Company contact information

Revive Therapeutics Ltd.

The Canadian Venture Building 82 Richmond Street East

M5C 1P1, Toronto

+888-901-0036

http://www.revivethera.com
address Revive Therapeutics Ltd(RVV)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.20% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.41% 101B
ARGENX SE Stock argenx SE
+4.40% 23.07B
BIONTECH SE Stock BioNTech SE
-12.34% 22.23B
GENMAB A/S Stock Genmab A/S
-4.36% 18.05B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.18B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.28% 16.94B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.10% 14.07B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.50% 12.35B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RVV Stock
  4. RVV Stock
  5. Company Revive Therapeutics Ltd